The Clinical Significance of T-cell Regulation in Hypertension Treatment

Miaoxin Fu ¹ Mingzhu Lv ¹ Jinyue Guo ¹ Aihua Mei ¹ Hang Qian ¹ Handong Yang ¹ Wenwen Wu ² Zhixin LIU ³ Jixin Zhong ⁴ Ying Wei ¹ Xinwen Min ¹ Haiyan Wu ¹ Jun Chen ^1*

• ¹ Affiliated Dongfeng Hospital, Hubei University of Medicine, Shiyan, China
• ² College of Public Health, Hubei University of Medicine, Shiyan, China
• ³ Shiyan Key Laboratory of Virology, Hubei University of Medicine, SHIYAN, China
• ⁴ Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

Hypertension, a globally prevalent condition, is closely associated with T cell-mediated inflammatory responses. Studies have shown that T cells, by secreting pro-inflammatory cytokines such as interferon-gamma (IFN-γ ), Interleukin-17 (IL-17), and Tumor necrosis factor-alpha (TNF-α), directly lead to vascular dysfunction and elevated blood pressure. The activation of Th1 and Th17 cell subsets, along with the dysfunction of regulatory T cells (Tregs), is a critical mechanism in the onset and progression of hypertension. This review explores the role of T cells in the pathophysiology of hypertension and discusses potential therapeutic strategies targeting T cell regulation, such as immunotherapy and gene-editing technologies. These emerging treatments hold promise for providing personalized therapeutic options for hypertensive patients, reducing inflammatory complications, and improving treatment outcomes.